Voyageur Pharmaceuticals Ltd. (VM.V)
CAD 0.11
(50.0%)
CAD 0.11
(50.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.22 Million CAD | 29.86% |
| 2022 | -1.75 Million CAD | 15.05% |
| 2021 | -2.04 Million CAD | -141.81% |
| 2020 | -1.11 Million CAD | -53.31% |
| 2019 | -550.17 Thousand CAD | 51.9% |
| 2018 | - CAD | -86.77% |
| 2017 | - CAD | -1076.09% |
| 2016 | -520.00 CAD | -3430.57% |
| 2015 | - CAD | 98.43% |
| 2014 | -94.46 Thousand CAD | -108.4% |
| 2013 | -45.32 Thousand CAD | 47.0% |
| 2012 | -85.51 Thousand CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -561.51 Thousand CAD | -70.9% |
| 2024 Q1 | -328.56 Thousand CAD | -16.6% |
| 2024 Q3 | -358.73 Thousand CAD | 36.11% |
| 2023 Q2 | -620.94 Thousand CAD | -66.41% |
| 2023 Q3 | -130.14 Thousand CAD | 79.04% |
| 2023 FY | - CAD | 22.78% |
| 2023 Q4 | -228.69 Thousand CAD | -75.72% |
| 2023 Q1 | -373.14 Thousand CAD | 34.05% |
| 2022 Q3 | -426.09 Thousand CAD | 10.44% |
| 2022 Q1 | -246.62 Thousand CAD | 52.37% |
| 2022 Q2 | -475.78 Thousand CAD | -92.92% |
| 2022 Q4 | -565.78 Thousand CAD | -32.78% |
| 2022 FY | - CAD | 15.05% |
| 2021 Q1 | -79.91 Thousand CAD | 52.55% |
| 2021 FY | - CAD | -141.81% |
| 2021 Q4 | -517.82 Thousand CAD | -40.3% |
| 2021 Q2 | -327.2 Thousand CAD | -309.46% |
| 2021 Q3 | -369.08 Thousand CAD | -12.8% |
| 2020 Q4 | -168.42 Thousand CAD | -1005.61% |
| 2020 Q3 | 18.59 Thousand CAD | 107.02% |
| 2020 Q1 | -408.64 Thousand CAD | -354.01% |
| 2020 FY | - CAD | -53.31% |
| 2020 Q2 | -264.93 Thousand CAD | 35.17% |
| 2019 Q2 | -108.1 Thousand CAD | 24.7% |
| 2019 Q4 | -90 Thousand CAD | 57.79% |
| 2019 Q3 | -213.21 Thousand CAD | -97.24% |
| 2019 FY | - CAD | 51.9% |
| 2019 Q1 | -143.56 Thousand CAD | 36.02% |
| 2018 FY | - CAD | -86.77% |
| 2018 Q1 | -141.35 Thousand CAD | -70.0% |
| 2018 Q2 | -154.77 Thousand CAD | -9.49% |
| 2018 Q3 | -628.79 Thousand CAD | -306.28% |
| 2018 Q4 | -224.4 Thousand CAD | 64.31% |
| 2017 Q1 | -45.31 Thousand CAD | -49.63% |
| 2017 Q3 | -220.05 Thousand CAD | 17.54% |
| 2017 FY | - CAD | -1076.09% |
| 2017 Q4 | -83.15 Thousand CAD | 62.21% |
| 2017 Q2 | -266.84 Thousand CAD | -488.93% |
| 2016 Q1 | -1092.00 CAD | 89.67% |
| 2016 Q2 | -15.45 Thousand CAD | -1315.11% |
| 2016 Q3 | -5496.00 CAD | 64.43% |
| 2016 Q4 | -30.28 Thousand CAD | -450.98% |
| 2016 FY | - CAD | -3430.57% |
| 2015 Q1 | -4025.00 CAD | 86.57% |
| 2015 FY | - CAD | 98.43% |
| 2015 Q4 | -10.56 Thousand CAD | -1185.77% |
| 2015 Q2 | 16.86 Thousand CAD | 518.88% |
| 2015 Q3 | -822.00 CAD | -104.88% |
| 2014 Q1 | -5945.00 CAD | 82.45% |
| 2014 FY | - CAD | -108.4% |
| 2014 Q4 | -29.96 Thousand CAD | -213.65% |
| 2014 Q3 | -9552.00 CAD | 80.51% |
| 2014 Q2 | -49 Thousand CAD | -724.27% |
| 2013 Q3 | -1854.00 CAD | 49.69% |
| 2013 Q4 | -33.86 Thousand CAD | -1726.81% |
| 2013 Q2 | -3685.00 CAD | 37.74% |
| 2013 Q1 | -5919.00 CAD | 74.34% |
| 2013 FY | - CAD | 47.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q4 | -23.07 Thousand CAD | -26.04% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | -44.14 Thousand CAD | 0.0% |
| 2012 Q3 | -18.3 Thousand CAD | 58.54% |
| 2011 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | -2.68 Million CAD | 54.466% |
| CanadaBis Capital Inc. | 5.67 Million CAD | 121.504% |
| Decibel Cannabis Company Inc. | 5.67 Million CAD | 121.499% |
| Delivra Health Brands Inc. | 2.35 Million CAD | 151.867% |
| Entourage Health Corp. | -21.39 Million CAD | 94.294% |
| Lifeist Wellness Inc. | -12.76 Million CAD | 90.439% |
| Cannara Biotech Inc. | 17.18 Million CAD | 107.104% |
| Medicure Inc. | 1.27 Million CAD | 195.911% |
| PharmaCielo Ltd. | -12.01 Million CAD | 89.841% |
| Rubicon Organics Inc. | 1.94 Million CAD | 162.677% |
| BioSyent Inc. | 9.05 Million CAD | 113.48% |